--- title: "Black Diamond Therapeutics IncQ) expected to post a loss of 25 cents a share - Earnings Preview" description: "Black Diamond Therapeutics IncQ) is projected to report a loss of 25 cents per share for the quarter ending June 30, 2025, with no change in revenue. Analysts maintain a \"buy\" rating, with a median 12" type: "news" locale: "en" url: "https://longbridge.com/en/news/251216874.md" published_at: "2025-08-01T13:45:21.000Z" --- # Black Diamond Therapeutics IncQ) expected to post a loss of 25 cents a share - Earnings Preview > Black Diamond Therapeutics IncQ) is projected to report a loss of 25 cents per share for the quarter ending June 30, 2025, with no change in revenue. Analysts maintain a "buy" rating, with a median 12-month price target of $11.00, significantly above its last closing price of $2.66. The mean earnings estimate has dropped by 89.5% in the last three months. Previous quarterly performances have consistently beaten estimates. - Black Diamond Therapeutics Inc (BDTX.OQ) (BDTX.O) is expected to show no change in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025 - ​LSEG’s mean analyst estimate for Black Diamond Therapeutics Inc is for a loss of 25 cents per share. - The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 5 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” - The mean earnings estimate of analysts had fallen by about 89.5% in the last three months. ​ - Wall Street’s median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.8% above its last closing price of $2.66 Previous quarterly performance (using preferred earnings measure in US dollars). ​ ### QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI ### ENDING ARTESTIMAT ESTIMATE MET, SE % ### E® MISSED Mar. 31 2025 0.49 0.02 0.98 Beat 4,511. 8 Dec. 31 2025 -0.31 -0.28 Beat 11 Sep. 30 2024 -0.38 -0.37 -0.28 Beat 25.1​ Jun. 30 2024 -0.38 -0.39 -0.36 Beat 7 ​​Mar. -0.42 -0.43 -0.35 Beat 19.5 31 2024 Dec. 31 2023 -0.45 -0.47 -0.34 Beat 27​ Sep. 30 2023 -0.44 -0.49 -0.45 Beat 7.5 Jun. 30 2023 -0.54 -0.54 -0.52 Beat 3 This summary was machine generated August 1 at 13:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) ### Related Stocks - [BDTX.US - Black Diamond Therapeutics](https://longbridge.com/en/quote/BDTX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Black Diamond Reports Promising Phase 2 Lung Cancer Data | Black Diamond Therapeutics announced promising preliminary data from its Phase 2 trial of silevertinib for non-small cel | [Link](https://longbridge.com/en/news/268450985.md) | | Black Diamond Therapeutics Announces Phase 2 Silevertinib Clinical Trial Results | Black Diamond Therapeutics will host a webcast on December 3, 2025, to present Phase 2 clinical trial results of silever | [Link](https://longbridge.com/en/news/268311074.md) | | AWM Investment Company Inc. Invests $775,000 in Black Diamond Therapeutics, Inc. $BDTX | AWM Investment Company Inc. has invested $775,000 in Black Diamond Therapeutics, acquiring 500,000 shares, representing | [Link](https://longbridge.com/en/news/256117972.md) | | Black Diamond Therapeutics to Present at Piper Sandler Healthcare Conference | Black Diamond Therapeutics Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conferen | [Link](https://longbridge.com/en/news/264716799.md) | | Black Diamond Therapeutics (BDTX) Has a New Rating from Freedom Capital Markets | According to TipRanks, Zubkov is a 2-star analyst with an average return of 1.7% and a 60.00% success rate. Zubkov cover | [Link](https://longbridge.com/en/news/259596964.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.